Evaluation of the Role of Tramadol 50mg as an Analgesic During Outpatient Hysteroscopy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02068209|
Recruitment Status : Completed
First Posted : February 21, 2014
Last Update Posted : April 6, 2015
|Condition or disease||Intervention/treatment||Phase|
|Pain||Drug: Tramadol Drug: Placebo||Phase 2|
This study is a prospective double blinded randomised controlled trial. 140 women will be recruited from the office hysteroscopy clinic in Cairo university hospitals.
All patients attending the outpatient hysteroscopy clinic will be invited to participate in the study. The invitation will include a clear full explanation of the study and patients will provide written consents. Only patients consenting to participate will be included in the trial.
Tramadol and placebo will be enclosed in sealed envelopes which will be numbered using a computer generated random table. Neither the patient nor the physician will be aware of the drug used. Patients will be categorized into 2 groups: Group I who will receive Tramadol 50mg (Tramadol, October Pharma, Giza, Egypt) 1 hour before the procedure, group II who will received a placebo acting as the control group.
Full history will be taken followed by general and local examination. The procedure will be done in the lithotomy position. Hysteroscopy will be done using a 5mm outer diameter continuous flow hysteroscope with a French working channel and a 30 degrees direction of view provided by Techno GmbH and CO. The hysteroscope will be introduced using the vaginoscopy technique, in which no speculum will be used. The cervix will be detected and the external os will be identified using the hysteroscope. The hysteroscope will be introduced in the uterine cavity. Saline will be used as the distension medium and the pressure will be set at 100mm Hg. The anterior wall, posterior wall and tubal ostea will be visualized, any polyps, adhesions septa, congenital malformations or submucous fibroids will be noted.
Base line characteristics will be compared and the main outcome measure will be patients' pain perception during the procedure and 30 minutes later, this will be determined using a visual analogue scale.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||140 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Supportive Care|
|Official Title:||Role of Tramadol 50mg in Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo Controlled Trial.|
|Study Start Date :||May 2014|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||March 2015|
Active Comparator: Tramadol
Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
Other Name: Tramadol 50mg
Placebo Comparator: Placebo
Patients will receive a placebo 1 hour before the procedure.
patients will receive a placebo 1 hour before outpatient hysteroscopy
- Pain perceived by the patient during the procedure [ Time Frame: 10 minutes after starting the procedure. ]Pain will be assessed by a visual analogue scale 10 minutes after starting the procedure.
- Pain perceived by the patient 30 minutes after the procedure. [ Time Frame: 30 minutes after the procedure. ]The level of pain will be assessed 30 minutes after the procedure by a visual analogue scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02068209
|Cairo University Hospitals|
|Principal Investigator:||AbdelGany MA Hassan, MRCOG, MD||Cairo University|